Risperdal® Stroke Lawyer

Approved in the 1990s as a type of new atypical anti-psychotic drug and thought to initially have fewer unwanted side effects, Risperdal® uses upon approval only included schizophrenia treatment. Risperdal® is often prescribed to control behavioral disorders in elderly patients with dementia and Alzheimers disease, including delusions, aggression, and anxiety, but the recent Risperdal® stroke announcement shows there is an increased risk in prescribing Risperdal® to a wider range of patients.

The concern with the growing power large pharmaceutical companies have has been a concern because of the influence exercised over safety regulations in pursuit of financial gain instead of patient safety. The worlds second biggest maker of medical products, Johnson & Johnsons Risperdal® schizophrenia drug has annual global sales of $2.1 billion. While a J&J spokesperson claimed an update to the Risperdal® label is indeed being made, and we will be sending out letters to health care professionals soon, the company had already issued Risperdal® warning letters to Canadian doctors and pharmacists six months before announcing Risperdal® side effect risks in the U.S.

In October 2002, J&J sent Canadian physicians and pharmacists Risperdal® warning letters that cited 37 reports of stroke or stroke-like events such as blood clots and hemorrhages that included 16 deaths. The Canadian Risperdal® warning letter also noted that two clinical trials of elderly dementia patients in which elderly Risperdal® dementia patients had a higher proportion of strokes or related events than patients that had received placebo. Risperdal® clinical trials have shown that 4% of Risperdal® patients suffered stroke or stroke-related events, opposed to just 2% of people receiving placebos. There were four Risperdal® deaths and just one death amongst placebo recipients.

Clinical trials testing Risperdal® in Alzheimer patients heightened concerns that the occurrence of serious Risperdal® side effects is higher than previously thought. Among 764 Risperdal® patients, 29 cases of stroke and stroke-related events were seen, in addition to four deaths. A Public Citizen consumer watchdog group pharmacist and research analyst thinks that the recent Risperdal® studies should push U.S. regulators to deeper examine if younger aged schizophrenia patients are also more prone to experiencing Risperdal® stroke and other side effects of Risperdal®.

For more information on Risperdal® side effects please contact us to confer with a Risperdal® lawyer.

Free Consultation Use this form to request a free consultation with a qualified attorney near you.

Note: The use of the Internet for communications with the firm will not establish an attorney-client relationship and messages containing confidential or time-sensitive information should not be sent. I agree that submitting this form does not create an attorney-client relationship and that the information I am providing may be used to check for conflicts of interest to determine if the firm can assist me with my legal inquiry. I Agree:*

ATTORNEY ADVERTISING
Flood Law Group, LLP
1101 Pennsylvania Avenue, Suite 600
Washington, DC 20004
Your privacy is important to us. Any information submitted to this form is guaranteed safe, secure, and private
FREE